By Stephen Nakrosis
Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five potential disease targets.
Under the terms of the deal, Lilly is granted world-wide exclusive license to utilize STAC-BBB for one initial target, and has the right to add up to four additional targets after paying additional licensed target fees.
The deal will see Sangamo receive $18 million as an upfront license fee. Under the terms of the agreement, Sangamo is eligible to receive up to $1.4 billion in additional license fees, milestone payments and tiered royalties, the companies said.
Sangamo is responsible for completing a technology transfer related to STAC-BBB, while Lilly is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of any resulting gene therapy products, the companies said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 03, 2025 16:30 ET (20:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。